Market Overview

UPDATE: Morgan Stanley Upgrades Bristol-Myers Squibb Co. on Potential of New Cancer Drugs

Related BMY
US Stock Futures Edge Higher Ahead Of Tiffany Earnings
Markets Marginally Higher On Light Volume And Encouraging Geopolitical Developments
The Stocks Already in Correction Mode (Fox Business)

In a report published Monday, Morgan Stanley analyst David Risinger upgraded the rating on Bristol-Myers Squibb Co. (NYSE: BMY) from Equal-Weight to Overweight, and raised the price target from $45.00 to $60.00.

In the report, Morgan Stanley noted, “Upgrading to OW and raising PT from $45 to $60 after raising 2020E EPS by 27%; $60 PT is up 23% from Friday's close. BMY is the leading contender to transform cancer treatment with new drugs that boost the immune system.”

Bristol-Myers Squibb Co. closed on Friday at $48.77.

Posted-In: David Risinger Morgan StanleyAnalyst Color Upgrades Analyst Ratings

 

Related Articles (BMY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters